Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 2/20 | 0.62 |
| ▸ | FYN | P06241 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18263126 | 0.82 | FYN (0.58) | USP7FYNMAP4K4CHEK2EGLN1 | |
| SCHEMBL18263118 | 0.81 | MAP4K4 (0.58) | USP7MAP4K4ALOX5EGLN1 | |
| SCHEMBL18263141 | 0.81 | FYN (0.57) | USP7FYNMAP4K4CHEK2EGLN1 | |
| SCHEMBL18240070 | 0.81 | FYN (0.58) | USP7FYNMAP4K4CHEK2EGLN1 | |
| SCHEMBL14157215 | 0.80 | FYN (0.59) | USP7FYNMAP4K4ALOX5EGLN1 | |
| SCHEMBL18263138 | 0.80 | MAP4K4 (0.53) | USP7FYNMAP4K4EGLN1ADORA1 | |
| SCHEMBL709795 | 0.79 | MAPT (0.59) | USP7FYNMAP4K4KDM4EMKNK1 | |
| SCHEMBL27650541 | 0.79 | USP7 (0.42) | USP7FYNMAP4K4KDM4EMKNK1 | |
| SCHEMBL971373 | 0.78 | MAP4K4 (0.80) | USP7FYNMAP4K4MKNK1CHEK2 | |
| SCHEMBL18263117 | 0.77 | LCK (0.47) | USP7FYNMAP4K4CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105037353-A | Synthetic method of 6-phenyl-8-methoxyethyl formate imidazo[1,2a]pyridine-3-ethyl formate | SHANDONG YOUBANG BIOCHEMICAL TECHNOLOGY CO LTD | 2015-11-11 | — | — | CN | claimed |
| CN-104910151-A | 6-phenyl-8-acetonitrile oxy imidazo [1,2-a] pyridine-3-carbonitrile preparation method | SHANDONG YOUBANG BIOCHEMICAL TECHNOLOGY CO LTD | 2015-09-16 | — | — | CN | claimed |
| EP-3145935-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS DAG-LIPASE INHIBITORS | Universiteit Leiden (NL) | 2017-03-29 | — | — | EP | disclosed |
| CN-103265477-B | Aminoheteroaryl compounds as protein kinase inhibitors | 苏根公司 | 2017-01-11 | — | — | CN | disclosed |
| WO-2016188972-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS DAG-LIPASE INHIBITORS | UNIVERSITEIT LEIDEN (NL) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016188972-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS DAG-LIPASE INHIBITORS | UNIVERSITEIT LEIDEN (NL) | 2016-12-01 | — | — | WO | disclosed |
| CN-105037353-A | Synthetic method of 6-phenyl-8-methoxyethyl formate imidazo[1,2a]pyridine-3-ethyl formate | SHANDONG YOUBANG BIOCHEMICAL TECHNOLOGY CO LTD | 2015-11-11 | — | — | CN | disclosed |
| CN-105037353-A | Synthetic method of 6-phenyl-8-methoxyethyl formate imidazo[1,2a]pyridine-3-ethyl formate | SHANDONG YOUBANG BIOCHEMICAL TECHNOLOGY CO LTD | 2015-11-11 | — | — | CN | disclosed |
| CN-104910151-A | 6-phenyl-8-acetonitrile oxy imidazo [1,2-a] pyridine-3-carbonitrile preparation method | SHANDONG YOUBANG BIOCHEMICAL TECHNOLOGY CO LTD | 2015-09-16 | — | — | CN | disclosed |
| CN-104910151-A | 6-phenyl-8-acetonitrile oxy imidazo [1,2-a] pyridine-3-carbonitrile preparation method | SHANDONG YOUBANG BIOCHEMICAL TECHNOLOGY CO LTD | 2015-09-16 | — | — | CN | disclosed |
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| CN-1777427-A | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN INC (US) | 2006-05-24 | — | — | CN | disclosed |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| WO-2006021884-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021886-A1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | ALK, MET, ERBB2 | USP7 2773/4885FYN 239/4885MAP4K4 106/4885 |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, CDC42BPA | USP7 1666/4885FYN 1377/4885MAP4K4 16/4885 |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | USP7 2848/4885FYN 817/4885MAP4K4 40/4885 |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | USP7 2903/4885FYN 840/4885MAP4K4 10/4885 |
| US-20140288086-A1 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | MET, MAP3K15, MAP3K1 | USP7 2385/4885FYN 1097/4885MAP4K4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.